Intal Spincaps

Pajjiż: New Zealand

Lingwa: Ingliż

Sors: Medsafe (Medicines Safety Authority)

Ingredjent attiv:

Sodium cromoglicate 20mg;  

Disponibbli minn:

Douglas Pharmaceuticals Limited

INN (Isem Internazzjonali):

Sodium cromoglicate 20 mg

Dożaġġ:

20 mg

Għamla farmaċewtika:

Powder for inhalation

Kompożizzjoni:

Active: Sodium cromoglicate 20mg  

Unitajiet fil-pakkett:

Blister pack, use with spinhaler, 50 dose units

Klassi:

Prescription

Tip ta 'preskrizzjoni:

Prescription

Manifatturat minn:

Aventis Pharma Manufacturing Pte Ltd

Sommarju tal-prodott:

Package - Contents - Shelf Life: Blister pack, use with spinhaler - 50 dose units - 36 months from date of manufacture stored at or below 30°C

Data ta 'l-awtorizzazzjoni:

1969-12-31

Karatteristiċi tal-prodott

INTAL SPINCAPS 
_SODIUM CROMOGLICATE 20 MG CAPSULES _
NAME OF THE MEDICINE 

INTAL SPINCAPS 
Sodium Cromoglicate 20 mg capsules. 
DESCRIPTION 

Sodium cromoglicate is a white or
almost white, crystalline powder.  The chemical 
name of sodium cromoglicate
is disodium 5,5’-[(2-hydroxypropane-1,3-
diyl)bis(oxy)]bis(4-oxo-4H-1-benzopyran-2-carboxylate.
 The molecular formula of 
sodium cromoglicate is C
23
H
14
Nz
2
O
11 
and the molecular weight is 512.3.  The 
structural formula is: 

INTAL SPINCAPS are micronised sodium cromoglicate in
a yellow/colourless 
gelatin capsule, overprinted with “SODIUM
CROMOGLICATE 20 mg” for use with 
the SPINHALER inhalation device. 
PHARMACOLOGY 
_MECHANISM OF ACTION _
Sodium cromoglicate is
a derivative of chromone-2-carboxylic acid, which inhibits 
the activation of many of the cell types involved in
the development and progression 
of asthma.  Thus, sodium cromoglicate prevents the formation of
IgE antibody or  
B lymphocytes, inhibits the release of inflammatory mediators
including cytokines 
form mast cells and reduces the chemotactic
activity of eosinophils and neutrophils.  
Activation and mediator release from monocytes and macrophages is
also reduced 
with sodium cromoglicate. 

Sodium cromoglicate inhibits antigen-induced early and late phase
airway obstruction 
in conscious animals and reduces the influx of
inflammatory cells into the airways.  
The drug also inhibits sensory nerve (C fibre) activation in
the dog lung and 
inflammatory responses in the airways of animals
induced by neuronal stimulation. 

This diverse range of activities of the
drug may be explained by the ability of sodium 
cromoglicate to block chloride channels in different
cell types that are important in 
cell activation. 

In acute bronchial provocation tests sodium cromoglicate has been
shown to inhibit or 
diminish the